YahooOctober 19, 2026 at 9:43 AM NY8 Days Ago
AbbVie vs. Bristol Myers: Is AbbVie’s Valuation Premium Worth Paying?
AbbVie Inc. (NYSE:ABBV) and Bristol-Myers Squibb Company (NYSE:BMY) are navigating a familiar pharmaceutical challenge, which revolves around replacing revenue from established medicines with newer products. Despite that broad similarity, investors are valuing their progress very differently. According to Yahoo Finance’s valuation data, AbbVie trades at 16.39 times forward earnings, compared with just 9.36 times for […]
What This Story Means
Claude is explaining the story in plain words…
Read the Full Story at the Source
The summary here comes from the news provider; the rest of the article lives on the publisher's site: Yahoo
